TGFB1 and heart disorder: Thus, TGF-β, through SMAD-dependent and -independent signaling, is associated with the onset of adverse cardiac pathologies and negative clinical outcomes, making preclinical research into this pathway for the treatment of cardiac disease an unmet medical need.